We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Gastrointestinal Bleeding Common Following Angioplasty for MI

By HospiMedica International staff writers
Posted on 26 Oct 2011
Patients with acute myocardial infarction (AMI) who undergo primary percutaneous coronary intervention (PCI) and antiplatelet therapy suffer a high incidence of upper gastrointestinal (GI) bleeding, according to a new study.

Researchers at Kaohsiung Chang Gung Memorial Hospital (Taiwan) conducted a prospective study involving 1,368 consecutive patients between May 2002 and September 2010 who experienced ST-segment elevation myocardial infarction (STEMI) and underwent subsequent primary PCI. More...
The researchers wished to investigate the incidence of composite major adverse upper gastrointestinal (UGI) events (MAUGIEs) in patients with acute STEMI who underwent primary PCI and routinely received dual-antiplatelet therapy. For the study, MAUGIEs were defined as gastric ulcer, duodenal ulcer, gastroduodenal ulcer, or UGI bleeding.

The results showed that about one quarter of patients who developed MAUGIEs in the hospital died before discharge, compared to only 10.4% of patients who had no major upper GI events. The investigators also reported that 16% of the patients who suffered MAGUIEs in the hospital developed recurrent major upper GI events during an average follow-up of about 3.3 years; the vast majority of these patients (97%) received long-term clopidogrel. Age, advanced Killip score, and respiratory failure were all significantly and independently predictive of in-hospital composite MAUGIEs. The study was published early online on September 19, 2011, in the American Journal of Cardiology.

“Prophylaxis against upper GI bleeding with a proton pump inhibitor is indicated for patients hospitalized for AMI, particularly those of advanced Killip classes,” said lead author Hon-Kan Yip, MD. “Since a PPI is known to interact with the antiplatelet agent clopidogrel resulting in an elevated risk of intra-coronary thrombosis, an interval of at least four hours is suggested between the administrations of these agents”

The Killip classification stratifies AMI patients; individuals with a low Killip class are less likely to die within the first 30 days after MI than individuals with a high Killip class. Killip class I includes individuals with no clinical signs of heart failure; class II includes individuals with rales or crackles in the lungs, and elevated jugular venous pressure; class III describes individuals with frank acute pulmonary edema; and class IV describes individuals in cardiogenic shock or hypotension, and evidence of peripheral vasoconstriction (oliguria, cyanosis, or sweating).

Related Links:
Kaohsiung Chang Gung Memorial Hospital



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.